Neuromodulation, Osteoarthritis (OA) of the Knee
Conditions
Brief summary
Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis
Interventions
DEVICEnerve stimulation using a nerve stimulator to the genicular nerve
temporary transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
DEVICEnerve stimulation using a nerve stimulator to the saphenous nerve
temporary transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
Sponsors
Tanta University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
This is a prospective, double-blinded, randomised study. The closed envelop randomization method will be used for the randomization of the patients who will be also blinded to group allocation.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain. 2. Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA). 3. patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.
Exclusion criteria
1. Patients with OA show improvement in pain after physiotherapy. 2. patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA. 3. pregnant patients. 4. patients on anticoagulation therapy, who were not permitted to stop anticoagulation. 5. patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis. 6. people who had received an intra-articular knee injection within the last 6 months. 7. Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in visual analogue scale after intervention. | immediately after intervention. | Decrement (clinical improvement) in visual analogue scale (VAS) immediately after intervention. The participant's knee discomfort was measured using a VAS. Participants were asked to score their level of pain on a 100-mm horizontal line, ranging from 0 to 100. |
Countries
Egypt
Contacts
CONTACTAliaa Mamdouh Abdelaziz Farag, MD
Outcome results
None listed